drugset / Trial / NCT00272025

Treatment Resistant Bipolar Depression

NCT00272025

Phase 1 Terminated 1 enrolled Queen's University
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.

Timeline

Start
2006-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 10 mg
Comparator Escitalopram Small molecule 20 mg

Indications